Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Open-label, Phase 3, Randomised Controlled Trial of Duvelisib Versus Investigator's Choice of Gemcitabine or Bendamustine in Patients With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

NCT06522737 is registered in ClinicalTrials.gov with SecuraBio as lead sponsor.

NCT NCT06522737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06522737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Open-label, Phase 3, Randomised Controlled Trial of Duvelisib Versus Investigator's Choice of Gemcitabine or Bendamustine in Patients With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
Lead sponsor
SecuraBio
Phase
Phase 3
Overall status
Recruiting
Start date
May 19, 2025
Completion date
December 31, 2028
Enrollment
124 (estimated)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma